Methodological Challenges and Preferred Approaches for the Economic Evaluation of CAR T Therapies: Evidence Review and Expert Consensus from NICE Appraisals.
BACKGROUND Chimeric antigen receptor T cell (CAR T) therapies pose challenges for economic evaluation because of complex treatment pathways and uncertainty around long-term outcomes. Within health technology assessment (HTA) bodies such as the National Institute for Health and Care Excellence (NICE), these features hav...